Protalix BioTherapeutics, Inc.

AMEX:PLX

Biotechnology

Healthcare
$3.02 +4.21%

+$0.09 today

Market cap
$254.64M
Beta
0.01
P/E (TTM)
11.0
EPS (TTM)
$0.19
52W Low $1.32High $3.19

Volume 0.96M

Average 0.81M

PLX Total Current Assets

All assets expected to be converted to cash or used up within one year.

Protalix BioTherapeutics, Inc.AMEX: PLX

Total Current Assets · Q1 FY2026 · quarter ended Mar 2026

Total current assets rises 42.7% from a year ago

Total current assets stood at $86.36M at the end of Q1 FY2026, up 42.7% from a year earlier and up 29.5% from the prior quarter. Over 3 fiscal years it compounded at +14.1% a year.

Context

  • Total current assets amounted to 84.4% of total assets at the end of Q1 FY2026, up 2.5 pp from a year earlier.
  • Total current assets increased in 2 of the last 3 fiscal years.

What to watch

Whether total current assets keeps rising in the next quarterly balance sheet after a +42.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$86.36M+29.5% QoQ
Last fiscal yearDec 2025
$66.67M+11.0% YoY
Year agoMar 2025
$60.51M+42.7% since
Total Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+42.7%——
1 year+11.0%——
3-year CAGR+14.1%——
5-year CAGR——
10-year CAGR——

Total Current Assets history

USD · from the balance sheet

Latest · FY2025
66.67M USD
Year-over-year change
+11.0%
4-year CAGR
+2.0%

Total Current Assets vs competitors

How PLX compares with its peers on the latest reported figures

  • PLX's Mar 2026 total current assets of $86.36M is the 3rd highest of the 4 companies compared; the peer median is $295.51M.
  • Its year-over-year change of +42.7% is the highest of 4, against a peer median of -6.0%.
  • Total current assets amounts to 84.4% of total assets for PLX, versus a peer median of 60.4%.
PLX Competitors Peer median
Total Current Assets for PLX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RAREUltragenyx Pharmaceutical Inc.Mar 2026$657M -6.0%+2.5%50.7%
PHARPharming Group N.V.Mar 2026$295.51M +38.0%+2.6%60.4%
PLXProtalix BioTherapeutics, Inc.Mar 2026$86.36M +42.7%+14.1%84.4%
PLYXPolaryx Therapeutics, Inc. Common StockMar 2026$3.5M -21.1%—100.0%
Peer median (excluding PLX) $295.51M-6.0%+2.5%60.4%

Competitors are the stored peer set for PLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents38.99M17.11M23.63M19.76M14.68M
Short-term Investments05.07M20.93M15.07M15.59M
Net Receivables3.44M4.59M5.27M2.91M8.84M
Inventory17.95M16.8M19.05M21.24M25.73M
Other Current Assets380K536K611K596K1.44M
Total Current Assets61.67M44.88M69.93M60.08M66.67M
Property, Plant & Equipment (Net)9.92M9.64M10.88M10.02M12.58M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets003.09M2.86M2.52M
Other Non-current Assets2.08M1.27M528K462K578K
Total Non-current Assets12M10.91M14.5M13.34M15.67M
Total Assets73.67M55.79M84.43M73.42M82.35M
Account Payables6.99M5.86M4.32M4.53M5.26M
Short-term Debt0021.66M00
Tax Payables0530K2.88M3.48M0
Deferred Revenue8.55M13.18M000
Other Current Liabilities1.51M11.06M4.94M1.81M2.31M
Total Current Liabilities33.18M32.43M45.53M25.62M26.52M
Long-term Debt27.89M28.19M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)11.79M0000
Other Non-current Liabilities2.47M1.64M714K559K661K
Total Non-current Liabilities46.53M34M5.34M4.59M7.6M
Total Liabilities79.7M66.43M50.87M30.21M34.12M
Common Stock46K54K73K76K80K
Retained Earnings(374.93M)(389.86M)(381.55M)(378.39M)(385M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity(6.04M)(10.64M)33.57M43.21M48.23M
Total Debt33.47M33.47M27.69M5.53M8.32M
Net Debt(5.52M)16.36M4.06M(14.23M)(6.36M)

Protalix BioTherapeutics, Inc.

AMEX:PLX

Intrinsic Alpha fair value

Locked

Current Price

$3.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.